---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002861"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:02:20.694616+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports ~$200M cash; DSMB clears third patient in Rett syndrome trial

## Summary
- DSMB cleared third pediatric patient for dosing in NGN-401 Phase 1/2 for Rett syndrome; dosing expected early Q1 2024.
- UK MHRA approved CTA for NGN-401, enabling trial expansion beyond US.
- Ended 2023 with ~$200M cash; cash runway into 2H 2026.
- Plan to report interim Phase 1/2 data for NGN-401 in 4Q 2024 and NGN-101 in 2H 2024; FDA discussions for NGN-101 in 2H 2024.
- Extended research collaboration with University of Edinburgh by three years; plan to advance one discovery product into clinic in 2025.

## SEC filing metadata
- accession: 0001193125-24-002861
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/0001193125-24-002861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/d828702d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002861
- JSON: https://secwatch.observer/filing/0001193125-24-002861.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.